SIBN
SI-BONE, Inc.19.42
+1.01+5.49%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Partnership details, guide conservatism.
Q&A shed light on the fresh Smith & Nephew trauma partnership, ramping from March via training and tray placements but excluded from 2026 guidance to let it season. Management framed conservative high-teens U.S. procedure growth against tough comps and tailwinds like INTRA Ti's ASC halo and reimbursement hikes, expecting back-half weighting. EBITDA rises but below $20M math amid sales adds and R&D. Gross margins dip to 78% from depreciation on capacity builds. Analysts pressed on guide conservatism; answers reaffirmed prudence. Q&A largely echoed prepared remarks. Watch partnership lift and product ramps.
Key Stats
Market Cap
842.66MP/E (TTM)
-Basic EPS (TTM)
-0.51Dividend Yield
0%Recent Filings
10-K
FY2025 results
SI-BONE delivered FY2025 revenue of $200.9M, up 20.2% y/y, with U.S. sales surging 20.6% on higher case volumes from an expanded product portfolio including iFuse TORQ TNT and iFuse INTRA, both FDA breakthrough devices launched in 2024. Gross margin ticked up to 79.6% on favorable product mix, yet operating expenses climbed 8.9% to $182.2M, narrowing net loss to $18.9M from $30.9M. Sales force grew to 89 territory managers and 320 third-party agents, boosting average revenue per territory manager to $2.1M (derived). Cash reserves stood at $147.8M with $35.6M debt at year-end. DOJ probe into healthcare compliance poses quarterly momentum risk.
8-K
Record FY25 revenue, leadership shift
SI-BONE crushed FY25 with $200.9M worldwide revenue, up 20.2%, positive adjusted EBITDA of $8.9M, and free cash flow turning positive in Q4. Leadership streamlined as CFO Anshul Maheshwari adds COO role. Signed 102-month lease for 50,485 sq ft in San Jose starting October 2026 at $128,737 initial monthly rent, with 6-month abatement. Guides 2026 revenue to $228.5M-$232.5M.
8-K
Preliminary Q4 revenue up 15%
10-Q
Q3 FY2025 results
SI-BONE posted Q3 revenue of $48.7M, up 20.6% y/y from $40.3M, with gross margin steady at 79.8%. Operating loss narrowed to $5.4M from $7.6M y/y, while net loss improved to $4.6M ($0.11/share) versus $6.6M ($0.16/share); YTD revenue hit $144.6M (+22.3% y/y), net loss $17.3M ($0.40/share). U.S. drove 95% of growth via higher case volumes and expanded portfolio. Cash plus short-term investments stood at $145.7M against $35.5M term debt (due 2029). Losses align across operating and net lines. Supply chain disruptions threaten implant availability.
8-K
Q3 revenue beats, guidance up
SI-BONE posted Q3 revenue of $48.7 million, up 20.6% year-over-year, with U.S. sales hitting $46.4 million (21.2% growth) and positive adjusted EBITDA of $2.3 million. Active U.S. physicians surged 27% to 1,530. Board trimmed to eight after Daniel Wolf's resignation on November 6; he shifts to 12-month consulting role. Raised 2025 revenue guidance to $198M-$200M.
BVS
Bioventus Inc.
7.52+0.02
EW
Edwards Lifesciences Corporatio
85.32+1.94
FZMD
Fuse Medical, Inc.
0.07+0.00
GMED
Globus Medical, Inc.
85.79-0.71
OFIX
Orthofix Medical Inc.
15.55-0.16
SSII
SS Innovations International In
5.50+0.41
TNON
Tenon Medical, Inc.
1.10+0.02
XTNT
Xtant Medical Holdings, Inc.
0.73+0.04
ZBH
Zimmer Biomet Holdings, Inc.
90.91-1.52
ZIMV
ZimVie Inc.
18.99+0.00